Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT

Measurable residual disease (MRD) prior to hematopoietic cell transplant (HCT) for acute myeloid leukemia (AML) in first complete morphological remission (CR1) is an independent predictor of outcome, but few studies address CR2. This analysis by the Acute Leukemia Working Party of the European Socie...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Blood Cancer J
Κύριοι συγγραφείς: Gilleece, Maria H., Shimoni, Avichai, Labopin, Myriam, Robinson, Stephen, Beelen, Dietrich, Socié, Gerard, Unal, Ali, Ganser, Arnold, Vitek, Antonin, Sengeloev, Henrik, Yakoub-Agha, Ibrahim, Tholouli, Eleni, Polge, Emmanuelle, Mohty, Mohamad, Nagler, Arnon
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Nature Publishing Group UK 2021
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8116335/
https://ncbi.nlm.nih.gov/pubmed/33980810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00479-3
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια